Affomix has struck a deal to use its technology to generate antibodies that can be used to hit therapeutic and diagnostic targets selected by Kalgene. The deal includes financial milestones, but the two companies didn't spell them out in their release.
"Our automated high-throughput procedures allow us to quickly identify highly specific antibodies against predetermined regions of target proteins. These antibodies are well suited for experimental use while serving as ideal starting points for development of diagnostic and therapeutic agents," says Michael Sherman, the president of Affomix.
- check out the Affomix release